Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Short Term Efficacy of Dysport and Dysport NG to Placebo, and to Assess Efficacy and Safety of Dysport NG of Subjects With Cervical Dystonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Dystonia with at least 18 months duration since onset.~* Previously untreated with Botulinum toxin-A (BTX-A) or -B or a minimum of 14 weeks since the last injection.~* TWSTRS score at baseline of: Total score ≥ 30, Severity Sub-Scale score ≥ 15, Disability Sub-Scale score ≥ 3, Pain Sub-Scale score ≥ 2.~Exclusion Criteria:~* Known hypersensitivity to Botulinum toxin (BTX) or related compounds or any component in the study drug formulation (including cow milk protein).~* Pure anterocollis or pure retrocollis.~* In apparent remission from Cervical Dystonia.~* Known clinically significant underlying swallowing or respiratory abnormality which might be exacerbated by BTX treatment.~* Previous poor response to BTX treatment or known presence of BTX neutralising antibodies.~* Previous phenol or alcohol injections into the neck muscles.~* Previous myotomy or denervation surgery involving the neck or shoulder region.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dysport NG (Type: EXPERIMENTAL): 500U (1mL) administered as intramuscular injection on day 1 of treatment cycle 1 and 2.~250U (0.5mL), 500U (1mL) or 750U (1.5mL) administered as intramuscular injection on day 1 of treatment cycle 3.~250U (0.5mL), 500U (1mL), 750U (1.5mL) or 1000U (2mL) administered as intramuscular injection on day 1 of treatment cycle 4 and 5.
- Dysport (Type: ACTIVE_COMPARATOR): 500U (1mL) injected as intramuscular injection on day 1 of treatment cycle 1.
- Placebo (Type: PLACEBO_COMPARATOR): 1mL administered as, intramuscular injection on day 1 of treatment cycle 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).